首页> 外文期刊>BioMed research international >Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches
【24h】

Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches

机译:血清氮物质和炎症参数在复杂的多发性治疗方法治疗中的复发式多发性硬化症患者的评估

获取原文
获取原文并翻译 | 示例
       

摘要

The role of nitric oxide and its reactive derivatives (NO_χ) is well known in the pathogenesis of multiple sclerosis, which is an inflammatory disease while NO_χ seems to be important in coordinating inflammatory response. The purpose of the present study was to assess serum NO_χ as one of the nitrogen species and inflammatory parameters in relapsing-remitting multiple sclerosis patients and to compare the effectiveness of various types of disease-modifying therapies that reduce nitric oxide and inflammatory biomarkers. Elevated NO_χ level was observed in patients who received the first-line disease-modifying therapy (interferons beta-1a and beta-1b) in comparison with the subjects treated with the second-line disease-modifying therapy (natalizumab; fingolimod) and healthy controls without significant differences in C-reactive protein and interleukin-1 beta. A negative correlation was observed between serum NO_χ level and the duration of multiple sclerosis confirmed in the whole study population and in subjects treated with the first-line agents. Only serum NO_χ, concentration could reveal a potential efficacy of disease-modifying therapy with a better reduction in NO_χ level due to the second-line agents of disease-modifying therapy.
机译:一氧化氮及其反应性衍生物(NO_1)的作用在多发性硬化症的发病机制中是众所周知的,这是一种炎症疾病,而NO_1似乎在协调炎症反应方面很重要。本研究的目的是评估血清NO_1作为氮物质和炎症参数之一,在重新分发多发性硬化患者中,并比较各种类型的疾病改性治疗的有效性,从而减少一氧化氮和炎性生物标志物。与用二线疾病修饰治疗(NaTalizumab; Fingolimod)和健康对照治疗的受试者相比,接受一线疾病修饰治疗(干扰素Beta-1a和Beta-1b)的患者观察到升高的NO_∞水平。没有C-反应蛋白和白细胞介素-1β的显着差异。在整个研究人群和用一线药物治疗的受试者中,在整个研究人群中确认的多发性硬化的持续时间之间观察到负相关性。只有血清NO_∞,浓度可以揭示疾病修饰治疗的潜在疗效,由于疾病修饰治疗的第二线代理,NO_∞水平的更好降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号